Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials

Stauffer, Virginia; Ascher-Svanum, Haya; Lin Liu; Ball, Tamara; Conley, Robert
January 2009
BMC Psychiatry;2009, Vol. 9, Special section p1
Academic Journal
Background: How long an antipsychotic is effective in maintaining response is important in choosing the correct treatment for people with schizophrenia. This post-hoc analysis describes maintenance of response over 24 or 28 weeks in people treated for schizophrenia with olanzapine, risperidone, quetiapine, ziprasidone, or aripiprazole. Methods: This was a post-hoc analysis using data from 5 double-blind, randomized, comparative trials of 24 or 28 weeks duration in which olanzapine was compared to risperidone (1 study; N = 339), quetiapine (1 study; N = 346), ziprasidone (2 studies; N = 548 and 394) or aripiprazole (1 study; N = 566) for treatment of schizophrenia. For each study, time to loss of response in patients who met criteria for response at Week 8 and the proportion of patients who lost response following Week 8 were compared by treatment group. The number needed to treat (NNT) with olanzapine rather than comparator to avoid loss of one additional responder over 24 or 28 weeks of treatment was calculated for each study. Results: Time maintained in response was significantly longer (p < .05) for olanzapine compared to risperidone, quetiapine, and ziprasidone. Olanzapine did not significantly differ from aripiprazole. The proportion of patients who lost response was significantly lower for olanzapine versus risperidone, quetiapine, and ziprasidone (p < .05). NNTs to avoid one additional patient with loss of response with olanzapine versus risperidone, quetiapine and ziprasidone were favourable, ranging from 5 to 9. Conclusion: During 24 and 28 weeks of treatment, the antipsychotics studied differed in the time that treated patients with schizophrenia remained in response and the proportion of patients who lost response. Olanzapine treatment resulted in a consistent and statistically significant advantage in maintenance of response compared to treatment with risperidone, quetiapine and ziprasidone; but not compared to treatment with aripiprazole.


Related Articles

  • Acadia drug subdues side effects from antipsychotic drug treatment.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p15 

    Reports that Acadia Pharmaceuticals has released clinical study data supporting the ability of ACP-103, a proprietary 5-HT2A inverse agonist, to reduce the side effects associated with antipsychotic drug treatment with haloperidol. Reduction of motor disturbances and hyperprolactinemia; Acadia's...

  • Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment. McGorry, Patrick D.; Cocks, John; Power, Paddy; Burnett, Peter; Harrigan, Susy; Lambert, Tim // Schizophrenia Research & Treatment;2011, p1 

    Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs) when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this...

  • Modelling and simulation of placebo effect: application to drug development in schizophrenia. Pilla Reddy, Venkatesh; Kozielska, Magdalena; de Greef, Rik; Vermeulen, An; Proost, Johannes // Journal of Pharmacokinetics & Pharmacodynamics;Jun2013, Vol. 40 Issue 3, p377 

    High and variable placebo effect (PE) within and among clinical trials can substantially affect conclusions about the efficacy of new drugs in the treatment of schizophrenia and other neuropsychiatric disorders. In recent years, it has become increasingly difficult to prove drug efficacy against...

  • Initial Severity of Schizophrenia and Efficacy of Antipsychotics. Furukawa, Toshi A.; Levine, Stephen Z.; Shiro Tanaka; Goldberg, Yair; Myrto Samara; Davis, John M.; Cipriani, Andrea; Leucht, Stefan // JAMA Psychiatry;Jan2015, Vol. 72 Issue 1, p14 

    IMPORTANCE: Antipsychotic drugs constitute the mainstay in the treatment of schizophrenia, and their efficacy is well established in hundreds of randomized clinical trials. However, it is not known whether they are effective or how effective they are across the wide range of baseline symptom...

  • COMMENTARY. Nicol, Ginger; Newcomer, John // Evidence Based Mental Health;Aug2008, Vol. 11 Issue 3, p81 

    The article presents comments on the study conducted by Sanjiv Kumra and colleagues about the safety and efficacy of antipsychotics for children and adolescents with early onset schizophrenia spectrum disorders (EOSS). According to the author, it is difficult to conclude on the comparative...

  • Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. Stauffer, Virginia; Karagianis, Jamie; Sutton, Virginia; Ascher-Svanum, Haya; Treuer, Tamas; de Lima, Mauricio Silva; Ball, Tamara; Poole-Hoffmann, Vicki; Tohen, Mauricio // Clinical Schizophrenia & Related Psychoses;Jul2008, Vol. 2 Issue 2, p136 

    Objective: All-cause discontinuation is considered a proxy for a medication's effectiveness. We examined the number needed to treat (NNT) to avoid all-cause medication discontinuation in head-to-head clinical trials of olanzapine versus other atypical antipsychotics. Methods: This was a post hoc...

  • Antipsychotic Polypharmacy Versus Monotherapy in Elderly Patients with Chronic Schizophrenia: A Clinical Trial. Mirabzadeh, Arash; Shemshadi, Hashem; Khodaei, Mohammad Reza; Sadighi, Gita; Hashempour, Sara; Mirabzadeh, Hossein; Biglarian, Akbar // Klinik Psikofarmakoloji Bulteni;2014, Vol. 24 Issue 4, p302 

    Objective: Antipsychotic polypharmacy in the elderly usually results in higher rates of interactions, side effects and increased cost. This research was designed to observe the benefits of replacing polypharmacy with a single medication in elderly patients with chronic schizophrenia. Methods:...

  • Amisulpride induced mania. Aggarwal, Ashish; Jain, Manish; Khandelwal, Ashish; Jiloha, R. C. // Indian Journal of Pharmacology;Apr2010, Vol. 42 Issue 2, p112 

    Amisulpride is an atypical antipsychotic used for the management of schizophrenia and other conditions like dysthymia. It has also been used for the management of bipolar disorders as an add on therapy. Here, we report a patient of schizophrenia who developed a manic episode while on amisulpride.

  • Paliperidone - a costly option for schizophrenia. Nikolaidou, Paraskevi; Chatzopoulos, Marinos; Seretis, Dionysis; Michael, Albert // Psychiatrist;Sep2013, Vol. 37 Issue 9, p308 

    A letter to the editor is presented in response to an article about the annual cost and efficacy of depot paliperidone used for the treatment of schizophrenia, which appeared in the previous issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics